$-0.37
(Market cap
$25,210 Mln
Revenue (TTM)
$5,820 Mln
P/E Ratio
15.8
P/B Ratio
4.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.3 %
-
ROCE
29.5 %
-
Industry P/E
37.32
-
EV/EBITDA
10.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$7.8
-
Face value
--
-
Shares outstanding
202,697,746
10 Years Aggregate
CFO
$3,462.76 Mln
EBITDA
$2,595.95 Mln
Net Profit
$1,896.67 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
| 29.2 | 7.8 | 30.3 | 46.8 | 25.4 | 10.9 | 4.5 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P 100
| 10.6 | 2.1 | 2.1 | 19.5 | 21.8 | 12.9 | 14.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
| 43.0 | 9.9 | -21.8 | 9.4 | -15.6 | -0.4 | 37.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
|
127.6 | 25,209.5 | 5,819.5 | 1,612.4 | 20.9 | 28 | 15.8 | 4.1 |
| 256.6 | 462,684.3 | 64,386.0 | 6,314.0 | 20.7 | -- | 75.2 | 50.5 | |
| 436.8 | 233,780.1 | 38,125.0 | 8,743.0 | 25.0 | 85.9 | 26.9 | 20.2 | |
| 66.7 | 136,882.3 | 49,187.0 | 9,282.0 | 27.7 | 45.5 | 14.8 | 6.0 | |
| 1,144.5 | 1,034,063.3 | 79,665.8 | 26,709.5 | 31.2 | 88.4 | 38.9 | 30.5 | |
| 150.7 | 180,636.7 | 30,456.0 | -3,240.0 | 29.7 | -18.8 | 17.7 | 15.6 | |
| 275.9 | 644,334.6 | 97,929.0 | 21,037.0 | 26.5 | 25.3 | 31.8 | 7.8 | |
| 150.4 | 367,583.9 | 66,400.0 | 3,173.0 | 10.9 | 6.7 | 122.1 | 9.0 | |
| 159.9 | 309,987.6 | 55,634.9 | 12,759.1 | 30.4 | 29.1 | 24.6 | 7.4 | |
| 28.5 | 158,393.9 | 63,696.0 | 4,335.0 | 10.8 | 5 | 36.6 | 1.9 |
Shareholding Pattern
View DetailsAbout Incyte (INCY)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF),... polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. Read more
-
CEO & Chairman
Mr. Herve Hoppenot
-
CEO & Chairman
Mr. Herve Hoppenot
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Incyte (INCY)
What is the current share price of Incyte Corp (INCY) Today?
The share price of Incyte Corp (INCY) is $127.64 (NASDAQ) as of 04-Sep-2026 13:37 EDT. Incyte Corp (INCY) has given a return of 25.42% in the last 3 years.
What is the current PB & PE ratio of Incyte Corp (INCY)?
The P/E ratio of Incyte Corp (INCY) is 15.84 times as on 28-Aug-2026, a 58 discount to its peers’ median range of 37.32 times.
The P/B ratio of Incyte Corp (INCY) is 4.08 times as on 28-Aug-2026, a 47 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
15.72 |
3.91 |
2024 |
418.09 |
3.96 |
2023 |
23.76 |
2.74 |
2022 |
53.01 |
4.13 |
2021 |
17.18 |
4.32 |
What is the 52 Week High and Low of Incyte Corp (INCY)?
The 52-week high and low of Incyte Corp (INCY) are Rs 132.58 and Rs 81.09 as of 05-Sep-2026.
What is the market cap of Incyte Corp (INCY)?
Incyte Corp (INCY) has a market capitalisation of $ 25,210 Mln as on 28-Aug-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Incyte Corp (INCY)?
Before investing in Incyte Corp (INCY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.